Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015258431> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2015258431 endingPage "S8" @default.
- W2015258431 startingPage "S8" @default.
- W2015258431 abstract "Transthyretin (TTR) amyloidosis is an underdiagnosed disease caused by destabilization of TTR due to pathogenic mutations or aging. Both pathogenic and protective mutations illuminate mechanisms of disease and potential interventions. AG10 is a selective, oral TTR stabilizer under development for transthyretin amyloidosis cardiomyopathy (ATTR-CM) that mimics a protective TTR mutation.This randomized, double-blind, placebo-controlled study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AG10 in ATTR-CM patients with symptomatic, chronic heart failure.ATTR-CM, New York Heart Association functional class II to III subjects (n = 49, mutant or wild-type) were randomized 1:1:1 to AG10 400 mg, AG10 800 mg, or placebo twice daily for 28 days. Safety and tolerability were assessed by clinical and laboratory criteria. AG10 plasma levels were measured. TTR stability was assessed by changes in serum TTR, and 2 established ex vivo assays (fluorescent probe exclusion and Western blot).AG10 treatment was well-tolerated, achieved target plasma concentrations and demonstrated near-complete stabilization of TTR. TTR stabilization was more complete and less variable at the higher dose with stabilization by fluorescent probe exclusion of 92 ± 10% (mean ± SD) at trough and 96 ± 9% at peak (both p < 10−12 vs. placebo). Average serum TTR increased by 36 ± 21% and 51 ± 38% at 400 and 800 mg, respectively (both p < 0.0001 vs. placebo). Baseline serum TTR in treated subjects was below normal in 80% of mutant and 33% of wild-type subjects. AG10 treatment restored serum TTR to the normal range in all subjects.AG10 has the potential to be a safe and effective treatment for patients with ATTR-CM. A phase 3 trial is ongoing. (Study of AG10 in Amyloid Cardiomyopathy; NCT03458130)" @default.
- W2015258431 created "2016-06-24" @default.
- W2015258431 creator A5056272438 @default.
- W2015258431 creator A5074656987 @default.
- W2015258431 date "2014-09-01" @default.
- W2015258431 modified "2023-10-03" @default.
- W2015258431 title "Euglenoid flagellates: Gene organization and expression, and biotechnological potency" @default.
- W2015258431 doi "https://doi.org/10.1016/j.jbiotec.2014.07.031" @default.
- W2015258431 hasPublicationYear "2014" @default.
- W2015258431 type Work @default.
- W2015258431 sameAs 2015258431 @default.
- W2015258431 citedByCount "0" @default.
- W2015258431 crossrefType "journal-article" @default.
- W2015258431 hasAuthorship W2015258431A5056272438 @default.
- W2015258431 hasAuthorship W2015258431A5074656987 @default.
- W2015258431 hasConcept C104317684 @default.
- W2015258431 hasConcept C121157162 @default.
- W2015258431 hasConcept C126322002 @default.
- W2015258431 hasConcept C134018914 @default.
- W2015258431 hasConcept C143065580 @default.
- W2015258431 hasConcept C153911025 @default.
- W2015258431 hasConcept C197934379 @default.
- W2015258431 hasConcept C207583985 @default.
- W2015258431 hasConcept C2776415932 @default.
- W2015258431 hasConcept C2778375690 @default.
- W2015258431 hasConcept C2779951007 @default.
- W2015258431 hasConcept C54355233 @default.
- W2015258431 hasConcept C71924100 @default.
- W2015258431 hasConcept C86803240 @default.
- W2015258431 hasConcept C98274493 @default.
- W2015258431 hasConceptScore W2015258431C104317684 @default.
- W2015258431 hasConceptScore W2015258431C121157162 @default.
- W2015258431 hasConceptScore W2015258431C126322002 @default.
- W2015258431 hasConceptScore W2015258431C134018914 @default.
- W2015258431 hasConceptScore W2015258431C143065580 @default.
- W2015258431 hasConceptScore W2015258431C153911025 @default.
- W2015258431 hasConceptScore W2015258431C197934379 @default.
- W2015258431 hasConceptScore W2015258431C207583985 @default.
- W2015258431 hasConceptScore W2015258431C2776415932 @default.
- W2015258431 hasConceptScore W2015258431C2778375690 @default.
- W2015258431 hasConceptScore W2015258431C2779951007 @default.
- W2015258431 hasConceptScore W2015258431C54355233 @default.
- W2015258431 hasConceptScore W2015258431C71924100 @default.
- W2015258431 hasConceptScore W2015258431C86803240 @default.
- W2015258431 hasConceptScore W2015258431C98274493 @default.
- W2015258431 hasLocation W20152584311 @default.
- W2015258431 hasOpenAccess W2015258431 @default.
- W2015258431 hasPrimaryLocation W20152584311 @default.
- W2015258431 hasRelatedWork W1823713625 @default.
- W2015258431 hasRelatedWork W2009464217 @default.
- W2015258431 hasRelatedWork W2130502067 @default.
- W2015258431 hasRelatedWork W2379610755 @default.
- W2015258431 hasRelatedWork W2563467731 @default.
- W2015258431 hasRelatedWork W2769929291 @default.
- W2015258431 hasRelatedWork W4220690714 @default.
- W2015258431 hasRelatedWork W4246662077 @default.
- W2015258431 hasRelatedWork W4284988915 @default.
- W2015258431 hasRelatedWork W4321255141 @default.
- W2015258431 hasVolume "185" @default.
- W2015258431 isParatext "false" @default.
- W2015258431 isRetracted "false" @default.
- W2015258431 magId "2015258431" @default.
- W2015258431 workType "article" @default.